Immuron Limited Sponsored ADR Stock News

Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales up 12% on prior quarter Canada Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp) Q1 sales up 63% on prior quarter USA Q1 sales AUD$0.3 million down 19% on prior ...

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm – 4:55pm U.S. Eastern Time).

MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controll...

MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.

MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical develop...